Trial Profile
Advantages of Magnesium isoglycyrrhizinate (MgIG) on protecting liver for patients with Allo-HSCT and effect of MgIG on graft-vetsus-host disease (GVHD)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 29 Sep 2016
Price :
$35
*
At a glance
- Drugs Isoglycyrrhizinate (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacodynamics
- 29 Sep 2016 New trial record